Single-Dose Malaria Drug Could Transform Treatment and Prevention Worldwide

Malaria remains one of the world's most serious infectious diseases, particularly in tropical and subtropical regions where access to healthcare can be difficult. A promising new antimalarial compound discovered by researchers at the University of Dundee could help simplify how malaria is treated and potentially prevented.

The compound, known as cabamiquine, is being investigated as part of a new treatment approach that could reduce the number of doses patients need to take. Early clinical research suggests that when cabamiquine is combined with the existing antimalarial medicine pyronaridine, the treatment may offer an effective and well-tolerated option for adults and teenagers.

The development is being welcomed as an important step in the global fight against malaria, a disease that continues to place a major burden on healthcare systems and communities around the world.

Why malaria treatment needs new options

Malaria is caused by parasites transmitted through the bites of infected mosquitoes. Although medicines and prevention programmes have helped reduce the impact of the disease in many areas, malaria continues to cause hundreds of millions of infections every year.

In 2024, there were an estimated 282 million cases of malaria worldwide, resulting in approximately 610,000 deaths. The continued spread of resistance to existing antimalarial medicines has also increased the need for new treatments.

One of the challenges in controlling malaria is ensuring that patients receive the correct treatment and complete the required course. In regions where healthcare resources are limited, completing a multi-dose treatment can be difficult.

This is where a single-dose malaria treatment could potentially make a significant difference.

What is cabamiquine?

Cabamiquine is a novel drug-like molecule discovered by scientists at the University of Dundee. Researchers have been working to develop it as a potential component of a simplified malaria treatment.

The compound is being studied in combination with pyronaridine, an established antimalarial medicine. Early-stage trial results indicate that the combination showed activity against malaria while maintaining a favourable safety profile in the adults and teenagers who participated in the study.

Importantly, the research suggests that cabamiquine could be administered as part of a single-dose treatment regimen.

A simpler dosing schedule could have important advantages. Patients may find it easier to complete treatment when they only need to take medicine once rather than following a longer schedule. This could also make treatment programmes easier to deliver in areas where medical services are difficult to access.

Potential benefits of a single-dose malaria treatment

The idea of reducing malaria treatment to a single dose is significant because effective treatment depends not only on how well a medicine works, but also on whether patients can access and complete it.

A complicated treatment schedule can create practical challenges. Patients may forget later doses, experience difficulty returning to a healthcare facility or stop treatment when symptoms improve.

A single-dose approach could help address some of these problems.

Researchers believe simplified dosing could also support wider malaria control efforts. Health workers operating in remote areas may be able to deliver treatment more efficiently, while public health programmes could potentially benefit from easier case management.

However, it is important to distinguish between promising early research and a medicine that is ready for widespread use. Cabamiquine remains under development, and additional clinical research will be required before its safety and effectiveness can be fully established.

Researchers see encouraging potential

Dr Beatriz Baragana, who was involved in the University of Dundee research team that discovered cabamiquine, described the development as an exciting step forward.

The research carried out in Dundee was supported by Medicines for Malaria Venture, or MMV, an organisation focused on developing and delivering new malaria medicines.

Professor Ian Gilbert, head of the University of Dundee's drug discovery unit, has also highlighted the potential importance of the compound's dosing characteristics. According to the research team, the combination appears promising not only because of its potential effectiveness, but also because it could be delivered as a single dose.

That feature could be particularly valuable in communities where consistent access to healthcare is challenging.

Further clinical trials will be important

Despite the encouraging early findings, much more research is needed before cabamiquine could become a widely available malaria medicine.

The initial study involved adults and teenagers. Future research will need to examine the treatment in larger and more diverse populations, including children.

Further trials will also be important for understanding how well the treatment performs in different malaria settings and whether it can maintain its effectiveness as resistance patterns change.

Medicines for Malaria Venture has indicated that cabamiquine combined with pyronaridine will continue into further development.

The findings from the study were published in The Lancet Infectious Diseases, providing a scientific basis for the next stage of investigation.

What this breakthrough could mean for malaria control

The potential importance of cabamiquine extends beyond treating individual infections. Researchers are also interested in how simpler treatment and prevention strategies could contribute to broader malaria elimination goals.

New medicines are particularly important as malaria parasites develop resistance to existing drugs. Without effective alternatives, resistance could make it increasingly difficult to treat infections and control transmission.

A medicine that combines effectiveness with a simplified dosing schedule could therefore offer advantages at both the individual and public health levels.

The road from an early clinical trial to an approved medicine is long, and promising results do not guarantee that a treatment will ultimately reach patients. Larger studies are needed to confirm the benefits and identify any risks that may not appear during early testing.

Nevertheless, the discovery of cabamiquine represents another example of how drug discovery research could contribute to the global effort against malaria.

A hopeful development in the fight against malaria

Malaria continues to affect millions of people every year, with the greatest burden falling on communities in countries where healthcare access can be limited. The disease also presents an evolving challenge as resistance to existing medicines increases.

Cabamiquine could offer a new approach by potentially allowing malaria treatment to be delivered in a single dose when used with pyronaridine. If future clinical trials confirm its effectiveness, safety and suitability for wider populations, the treatment could help make malaria care simpler and more accessible.

For now, the compound remains under investigation. The next stages of clinical development will determine whether the early promise translates into a practical new malaria medicine.

The research nevertheless provides a reason for cautious optimism. A simpler treatment regimen, combined with continued investment in malaria research, could become an important part of efforts to reduce illness and deaths from one of the world's most persistent infectious diseases.

Source: The Independent, published 17 August 2026.

Disclaimer: This article is for general informational and educational purposes only. It is based on the source material provided and should not be considered medical advice. The development discussed is an investigational treatment, and early clinical findings do not establish that a medicine is safe, effective or approved for general use. Readers should consult qualified healthcare professionals and trusted public health authorities for medical guidance.